ArticleVaccines2026
Real-World Utilization of the Novavax Adjuvanted Recombinant Protein COVID-19 Vaccine in France During the 2022-2024 Period.
Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
BACKGROUND/
objectivesThe Novavax COVID-19 vaccine (Nuvaxovid™) was authorized in France in December 2021, assisting in ending the global pandemic and providing an alternative to other COVID-19 vaccines. Understanding Nuvaxovid recipients' profile is essential for guiding vaccination decision-making and maintaining protection amid declining COVID-19 vaccination rates.
methodsThis retrospective, observational study characterizes the evolution of French Nuvaxovid recipients' demographic and clinical characteristics using the Système National des Données de Santé (SNDS) database. Five study seasons (spring 2022, autumn 2022, spring 2023, autumn 2023, spring 2024) were defined based on French vaccination guidelines and Nuvaxovid authorization dates. T-test and Chi-square tests were used to compare between consecutive seasons and subgroups.
resultsNuvaxovid administration was reported in 9805 recipients during spring 2022, 5601 during autumn 2022, 531 during spring 2023, 980 during autumn 2023, and 909 during spring 2024. Statistically significant increases in the proportions of high-risk (spring 2022: 35.4%, spring 2024: 90.5%) and ≥65-year-old (spring 2022: 19.9%, spring 2024: 84.4%) Nuvaxovid recipients were observed,
conclusionsThe use of Nuvaxovid evolved in accordance with changing clinical recommendations, and mix-and-match vaccination strategies and heterologous vaccination patterns suggest that it served as an important protein-based alternative for those switching from other COVID-19 vaccines. Nuvaxovid offers a valuable choice, so that the most vulnerable continue to be vaccinated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.